Back to Journals » Journal of Asthma and Allergy » Volume 13

Asthma and COVID-19: In Defense of Evidence-Based SABA

Authors Amirav I, Newhouse MT

Received 1 September 2020

Accepted for publication 28 September 2020

Published 15 October 2020 Volume 2020:13 Pages 505—508

DOI https://doi.org/10.2147/JAA.S279061

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Amrita Dosanjh


Israel Amirav,1 Michael T Newhouse2

1Pediatric Department, University of Alberta, Edmonton, AB T6G2C6, Canada; 2Firestone Institute for Respiratory Health, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada

Correspondence: Israel Amirav
Dana-Dwek Children’s Hospital, Tel Aviv, Israel
Tel +1 972-55-6649359
Email [email protected]

Abstract: There have recently been major objections to the use of short-acting beta-agonist (SABA) in episodic acute asthma culminating in a call for replacing SABA with combination of inhaled corticosteroids and long-acting beta-agonists despite little evidence supporting this point of view. It is regrettable to note that this attack on SABA occurs in the midst of an unprecedented demand for, and shortage of, SABA inhalers during the current COVID-19 pandemic, and the worldwide efforts to increase SABA supplies. In this commentary, we defend the well-established role of SABA and argue that the call for the phase out of SABA is inappropriate, since it is not solidly evidence based.

Keywords: asthma, beta-agonists, COVID-19, inhalers

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]